Predicting CAR T-cell Toxicity: Insurance for CAR Crashes
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H
. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448.
PMC: 5996391.
DOI: 10.1056/NEJMoa1709866.
View
2.
Kadauke S, Myers R, Li Y, Aplenc R, Baniewicz D, Barrett D
. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021; 39(8):920-930.
PMC: 8462622.
DOI: 10.1200/JCO.20.02477.
View
3.
Zandaki D, Selukar S, Bi Y, Li Y, Zinsky M, Bonifant C
. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2024; 9(2):270-279.
PMC: 11782822.
DOI: 10.1182/bloodadvances.2024014027.
View
4.
Schultz L, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J
. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2021; 40(9):945-955.
PMC: 9384925.
DOI: 10.1200/JCO.20.03585.
View
5.
Brudno J, Kochenderfer J
. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024; 21(7):501-521.
PMC: 11529341.
DOI: 10.1038/s41571-024-00903-0.
View